Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy DOI Creative Commons
Noemi Fiaschini, Patrizia Nadia Hanieh,

Daniela Ariaudo

и другие.

Pharmaceutics, Год журнала: 2024, Номер 16(12), С. 1593 - 1593

Опубликована: Дек. 13, 2024

Background/Objectives: This study aimed to develop a novel nanotechnological slow-release drug delivery platform based on hyaluronic acid Microsponge (MSP) for the subcutaneous administration of methotrexate (MTX) in treatment rheumatoid arthritis (RA). RA is chronic autoimmune disease characterized by joint inflammation and damage, while MTX common disease-modifying antirheumatic (DMARD), conventional use which limited adverse effects lack release control. Methods: MSP were synthesized as freeze-dried powder increase their stability allow facile reconstitution prior precise dosing. Results: A highly stable rounded-shaped micrometric MSP, an open porosity inner structure, achieved both high loading efficiency slow after injection. Our assays indeed demonstrated characteristic profile consisting very burst first few hours, followed sustained over month. By means preclinical rat model RA, MTX-loaded proved nearly double therapeutic efficacy compared sole MTX, according steep reduction arthritic score control groups. The was replicated twice confirm this improvement performance safety MSP. Conclusions: suggests that holds significant potential clinical improving therapy enabling thereby enhancing outcomes minimizing side associated with burst-release administration.

Язык: Английский

Advancements in rheumatoid arthritis therapy: a journey from conventional therapy to precision medicine via nanoparticles targeting immune cells DOI

Anwesha Laha,

Simran Nasra, Dhiraj Bhatia

и другие.

Nanoscale, Год журнала: 2024, Номер 16(32), С. 14975 - 14993

Опубликована: Янв. 1, 2024

Rheumatoid arthritis (RA) is a progressive autoimmune disease that mainly affects the inner lining of synovial joints and leads to chronic inflammation. While RA not known as lethal, recent research indicates it may be silent killer because its strong association with an increased risk lung heart diseases. Patients develop these systemic consequences due regular uptake heavy drugs such disease-modifying antirheumatic medications (DMARDs), glucocorticoids (GCs), nonsteroidal anti-inflammatory medicines (NSAIDs),

Язык: Английский

Процитировано

6
Bridging the gap in rheumatoid arthritis treatment with hyaluronic acid-based drug delivery approaches DOI
Sakshi Priya,

Jeevika Daryani,

Vaibhavi Meghraj Desai

и другие.

International Journal of Biological Macromolecules, Год журнала: 2024, Номер 271, С. 132586 - 132586

Опубликована: Май 23, 2024

Язык: Английский

Процитировано

5
Xuetongsu Ameliorates Synovial Inflammatory Hyperplasia in Rheumatoid Arthritis by Inhibiting JAK2/STAT3 and NF-κB Signaling Pathways DOI

Yasi Deng,

Yuxin Chen, Hao Zheng

и другие.

Journal of Ethnopharmacology, Год журнала: 2024, Номер 337, С. 118786 - 118786

Опубликована: Сен. 6, 2024

Язык: Английский

Процитировано

2
MCP-1 and IL-4 encapsulated hydrogel particles with macrophages enrichment and polarization capabilities for systemic lupus erythematosus treatment DOI
Shengjie Zhu,

Danqing Huang,

Qichen Luan

и другие.

Nano Research, Год журнала: 2024, Номер 17(9), С. 8316 - 8324

Опубликована: Июнь 26, 2024

Язык: Английский

Процитировано

0
Application of Microsponge Drug Platform to Enhance Methotrexate Administration in Rheumatoid Arthritis Therapy DOI Creative Commons
Noemi Fiaschini, Patrizia Nadia Hanieh,

Daniela Ariaudo

и другие.

Pharmaceutics, Год журнала: 2024, Номер 16(12), С. 1593 - 1593

Опубликована: Дек. 13, 2024

Background/Objectives: This study aimed to develop a novel nanotechnological slow-release drug delivery platform based on hyaluronic acid Microsponge (MSP) for the subcutaneous administration of methotrexate (MTX) in treatment rheumatoid arthritis (RA). RA is chronic autoimmune disease characterized by joint inflammation and damage, while MTX common disease-modifying antirheumatic (DMARD), conventional use which limited adverse effects lack release control. Methods: MSP were synthesized as freeze-dried powder increase their stability allow facile reconstitution prior precise dosing. Results: A highly stable rounded-shaped micrometric MSP, an open porosity inner structure, achieved both high loading efficiency slow after injection. Our assays indeed demonstrated characteristic profile consisting very burst first few hours, followed sustained over month. By means preclinical rat model RA, MTX-loaded proved nearly double therapeutic efficacy compared sole MTX, according steep reduction arthritic score control groups. The was replicated twice confirm this improvement performance safety MSP. Conclusions: suggests that holds significant potential clinical improving therapy enabling thereby enhancing outcomes minimizing side associated with burst-release administration.

Язык: Английский

Процитировано

0